Bupropion for the treatment of seasonal affective disorder

Bibliography

• Partonen T, Lönnqvist J. Seasonal affective disorder. Lancet 1998;352(9137):1369-74
   PubMed Web of Science ®Google Scholar
• Wehr TA, Giesen HA, Schulz PM, et al. Contrasts between symptoms of summer depression and winter depression. J Affect Disord 1991;23(4):173-83
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental health disorders. Revised 4th edition. American Psychiatric Association, Washington DC; 1994
   Google Scholar
• Kurlansik SL, Ibay AD. Seasonal affective disorder. Am Fam Physician 2012;86(11):1037-41
   PubMed Web of Science ®Google Scholar
• Levitan RD. The chronobiology and neurobiology of winter seasonal affective disorder. Dialogues Clin Neurosci 2007;9(3):315-24
   PubMedGoogle Scholar
• Clinical Study Registry. GlaxoSmithKline. GlaxoSmithKline, Middlesex, United Kingdom; 2013. Available from: http://www.gsk-clinicalstudyregister.com/ [Last accessed 3 February 2013]
   Google Scholar
• Ravindran AV, Lam RW, Filteau MJ, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. J Affect Disord 2009;117(Suppl 1):S54-64
   PubMed Web of Science ®Google Scholar
• Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005;162(4):656-62
   PubMed Web of Science ®Google Scholar
• Partonen T, Lönnqvist J. Prevention of winter seasonal affective disorder by bright-light treatment. Psychol Med 1996;26(5):1075-80
   PubMed Web of Science ®Google Scholar
• Terman M, Terman JS. Treatment of seasonal affective disorder with a high-output negative ionizer. J Altern Complement Med 1995;1(1):87-92
   PubMedGoogle Scholar
• Terman M, Terman JS. Controlled trial of naturalistic dawn simulation and negative air ionization for seasonal affective disorder. Am J Psychiatry 2006;163(12):2126-33
   PubMed Web of Science ®Google Scholar
• Flory R, Ametepe J, Bowers B. A randomized, placebo-controlled trial of bright light and high-density negative air ions for treatment of Seasonal Affective Disorder. Psychiatry Res 2010;177(1-2):101-8
   PubMed Web of Science ®Google Scholar
• Avery DH, Eder DN, Bolte MA, et al. Dawn simulation and bright light in the treatment of SAD: a controlled study. Biol Psychiatry 2001;50(3):205-16
   PubMed Web of Science ®Google Scholar
• Rohan KJ, Roecklein KA, Tierney Lindsey K, et al. A randomized controlled trial of cognitive-behavioral therapy, light therapy, and their combination for seasonal affective disorder. J Consult Clin Psychol 2007;75(3):489-500
   PubMed Web of Science ®Google Scholar
• Moscovitch A, Blashko CA, Eagles JM, et al. A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl) 2004;171(4):390-7
   PubMed Web of Science ®Google Scholar
• Lam RW, Gorman CP, Michalon M, et al. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 1995;152(12):1765-70
   PubMed Web of Science ®Google Scholar
• Lam RW, Levitt AJ, Levitan RD, et al. The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry 2006;163(5):805-12
   PubMed Web of Science ®Google Scholar
• Ruhrmann S, Kasper S, Hawellek B, et al. Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med 1998;28(4):923-33
   PubMed Web of Science ®Google Scholar
• Partonen T, Lönnqvist J. Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord 1996;41(2):93-9
   PubMed Web of Science ®Google Scholar
• Lingjaerde O, Reichborn-Kjennerud T, Haggag A, et al. Treatment of winter depression in Norway. II. A comparison of the selective monoamine oxidase A inhibitor moclobemide and placebo. Acta Psychiatr Scand 1993;88(5):372-80
   PubMed Web of Science ®Google Scholar
• Pjrek E, Winkler D, Stastny J, et al. Escitalopram in seasonal affective disorder: results of an open trial. Pharmacopsychiatry 2007;40(1):20-4
   PubMed Web of Science ®Google Scholar
• Pjrek E, Willeit M, Praschak-Rieder N, et al. Treatment of seasonal affective disorder with duloxetine: an open-label study. Pharmacopsychiatry 2008;41(3):100-5
   PubMed Web of Science ®Google Scholar
• Pjrek E, Winkler D, Konstantinidis A, et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl) 2007;190(4):575-9
   PubMed Web of Science ®Google Scholar
• Hilger E, Willeit M, Praschak-Rieder N, et al. Reboxetine in seasonal affective disorder: an open trial. Eur Neuropsychopharmacol 2001;11(1):1-5
   PubMed Web of Science ®Google Scholar
• Shen J, Kennedy SH, Levitan RD, et al. The effects of nefazodone on women with seasonal affective disorder: clinical and polysomnographic analyses. J Psychiatry Neurosci 2005;30(1):11-16
   PubMed Web of Science ®Google Scholar
• Dilsaver SC, Jaeckle RS. Winter depression responds to an open trial of tranylcypromine. J Clin Psychiatry 1990;51(8):326-9
   PubMed Web of Science ®Google Scholar
• Dilsaver SC, Qamar AB, Del Medico VJ. The efficacy of bupropion in winter depression: results of an open trial. J Clin Psychiatry 1992;53(7):252-5
   PubMed Web of Science ®Google Scholar
• Hesselmann B, Habeler A, Praschak-Rieder N, et al. Mirtazapine in seasonal affective disorder (SAD): a preliminary report. Hum Psychopharmacol 1999;14(1):59-62
   Web of Science ®Google Scholar
• Thorell LH, Kjellman B, Arned M, et al. Light treatment of seasonal affective disorder in combination with citalopram or placebo with 1-year follow-up. Int Clin Psychopharmacol 1999;14(Suppl 2):S7-11
   PubMedGoogle Scholar
• Kasper S. Treatment of seasonal affective disorder (SAD) with hypericum extract. Pharmacopsychiatry 1997;30(Suppl 2):89-93
   PubMedGoogle Scholar
• Martinez B, Kasper S, Ruhrmann S, Moller HJ. Hypericum in the treatment of seasonal affective disorders. J Geriatr Psychiatry Neurol 1994;7(Suppl 1):S29-33
   PubMedGoogle Scholar
• Wheatley D. Hypericum in seasonal affective disorder (SAD). Curr Med Res Opin 1999;15(1):33-7
   PubMed Web of Science ®Google Scholar
• McGrath RE, Buckwald B, Resnick EV. The effect of L-tryptophan on seasonal affective disorder. J Clin Psychiatry 1990;51(4):162-3
   PubMed Web of Science ®Google Scholar
• Modell JG, Rosenthal NE, Harriett AE, et al. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry 2005;58(8):658-67
   PubMed Web of Science ®Google Scholar
• Martiny K, Lunde M, Simonsen C, et al. Relapse prevention by citalopram in SAD patients responding to 1 week of light therapy. A placebo-controlled study. Acta Psychiatr Scand 2004;109(3):230-4
   PubMed Web of Science ®Google Scholar
• WELLBUTRIN® (bupropion hydrochloride) Tablets. GlaxoSmithKline. GlaxoSmithKline, Research Triangle Park, NC; 2011. Available from: http://us.gsk.com/products/assets/us_wellbutrin_tablets.pdf [Last accessed 26 December 2012]
   Google Scholar
• APLENZIN® (bupropion hydrobromide) Extended-Release Tablets. sanofi-aventis U.S. LLC. sanofi-aventis U.S. LLC, Bridgewater, NJ; 2012. Available from: http://products.sanofi.us/aplenzin/aplenzin.pdf [Last accessed 26 December 2012]
   Google Scholar
• WELLBUTRIN SR® (bupropion hydrochloride) Sustained-Release Tablets. GlaxoSmithKline. GlaxoSmithKline, Research Triangle Park, NC; 2011. Available from: http://us.gsk.com/products/assets/us_wellbutrinSR.pdf [Last accessed 26 December 2012]
   Google Scholar
• ZYBAN SR® (bupropion hydrochloride) Sustained-Release Tablets. GlaxoSmithKline. GlaxoSmithKline, Research Triangle Park, NC; 2012. Available from: http://us.gsk.com/products/assets/us_zyban.pdf [Last accessed 26 December 2012]
   Google Scholar
• WELLBUTRIN XL® (bupropion hydrochloride) tablet, extended release. BTA Pharmaceuticals. BTA Pharmaceuticals, Inc., Bridgewater, NJ; 2011. Available from: http://www.wellbutrinxl.com/Portals/24/Documents/WellbutrinXL_Full_Prescribing_Information.pdf [Last accessed 26 December 2012]
   Google Scholar
• Bowers GN Jr, Onoroski M. Hyperchloremia and the incidence of bromism in 1990. Clin Chem 1990;36(8 Pt 1):1399-403
   PubMed Web of Science ®Google Scholar
• van Gelderen CE, Savelkoul TJ, Blom JL, et al. The no-effect level of sodium bromide in healthy volunteers. Hum Exp Toxicol 1993;12(1):9-14
   PubMed Web of Science ®Google Scholar
• EMEA/MRL/182/97-FINAL: bromide, Sodium salt, Summary Report. Committee for veterinary medicinal products. The European Agency for the Evaluation of Medicinal Products. March 1997. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500011113.pdf [Last accessed 12 March 2013]
   Google Scholar
• Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6(4):159-66
   PubMedGoogle Scholar
• Learned-Coughlin SM, Bergstrom M, Savitcheva I, et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003;54(8):800-5
   PubMed Web of Science ®Google Scholar
• Arias HR. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int J Biochem Cell Biol 2009;41(11):2098-108
   PubMed Web of Science ®Google Scholar
• Miller L, Griffith J. A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology (Berl) 1983;80(3):199-205
   PubMed Web of Science ®Google Scholar
• Griffith JD, Carranza J, Griffith C, Miller LL. Bupropion: clinical assay for amphetamine-like abuse potential. J Clin Psychiatry 1983;44(5 Pt 2):206-8
   PubMed Web of Science ®Google Scholar
• McCormick J. Recreational bupropion abuse in a teenager. Br J Clin Pharmacol 2002;53(2):214
   PubMed Web of Science ®Google Scholar
• Khurshid KA, Decker DH. Bupropion insufflation in a teenager. J Child Adolesc Psychopharmacol 2004;14(1):157-8
   PubMed Web of Science ®Google Scholar
• Hill S, Sikand H, Lee J. A case report of seizure induced by bupropion nasal insufflation. Prim Care Companion J Clin Psychiatry 2007;9(1):67-9
   PubMedGoogle Scholar
• Kim D, Steinhart B. Seizures induced by recreational abuse of bupropion tablets via nasal insufflation. CJEM 2010;12(2):158-61
   PubMedGoogle Scholar
• Findlay JW, Van Wyck Fleet J, Smith PG, et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981;21(2):127-35
   PubMed Web of Science ®Google Scholar
• Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 2005;27(11):1685-95
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Study 201. Single-Dose Bioequivalence of WELLBUTRIN® Sustained-Release Tablets Versus WELLBUTRIN Immediate-Release Tablets in Healthy Male Volunteers. A Pilot Study. GlaxoSmithKline, Research Triangle Park, NC; 1991
   Google Scholar
• GlaxoSmithKline. Study 206. Steady-state bioequivalence evaluation of bupropion sustained-release and bupropion immediate-release tablets in healthy male volunteers. GlaxoSmithKline, Research Triangle Park, NC; 1992
   Google Scholar
• GlaxoSmithKline. Study AK1BIOVAIL2543. A two-way, crossover, steady state, multiple-dose, open-label, fasting, comparative bioavailability study of bupropion HCI 300 mg extended release tablets (1 X 300 mg q.d.) versus WELLBUTRIN 100 mg tablets (t.i.d.) in normal healthy non-smoking male and female subjects. GlaxoSmithKline, Research Triangle Park, NC; 2001
   Google Scholar
• GlaxoSmithKline. Study AK1BIOVAIL2572. A two-way, steady state, crossover, open-label, multiple-dose, fasting, comparative bioavailability study of bupropion HCI 300 mg extended-release tablets versus ZYBAN 150 mg tablets in normal healthy non-smoking male and female subjects. GlaxoSmithKline, Research Triangle Park, NC; 2002
   Google Scholar
• Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997;37(8):737-43
   PubMed Web of Science ®Google Scholar
• Kokras N, Dalla C, Papadopoulou-Daifoti Z. Sex differences in pharmacokinetics of antidepressants. Expert Opin Drug Metabol Toxicol 2011;7(2):213-26
   PubMed Web of Science ®Google Scholar
• Schroeder DH. Metabolism and kinetics of bupropion. J Clin Psychiatry 1983;44(5 Pt 2):79-81
   PubMed Web of Science ®Google Scholar
• Coles R, Kharasch ED. Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes. Pharm Res 2008;25(6):1405-11
   PubMed Web of Science ®Google Scholar
• Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000;28(10):1176-83
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Tolonen A, Uusitalo J, et al. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005;77(6):553-9
   PubMed Web of Science ®Google Scholar
• Hogeland GW, Swindells S, McNabb JC, et al. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 2007;81(1):69-75
   PubMed Web of Science ®Google Scholar
• Hesse LM, Greenblatt DJ, von Moltke LL, Court MH. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J Clin Pharmacol 2006;46(5):567-76
   PubMed Web of Science ®Google Scholar
• Park J, Vousden M, Brittain C, et al. Dose-related reduction in bupropion plasma concentrations by ritonavir. J Clin Pharmacol 2010;50(10):1180-7
   PubMed Web of Science ®Google Scholar
• Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995;15(5):327-33
   PubMed Web of Science ®Google Scholar
• Reese MJ, Wurm RM, Muir KT, et al. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 2008;36(7):1198-201
   PubMed Web of Science ®Google Scholar
• Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009;70(12):1688-97
   PubMed Web of Science ®Google Scholar
• Weintraub D. Nortriptyline toxicity secondary to interaction with bupropion sustained-release. Depress Anxiety 2001;13(1):50-2
   PubMed Web of Science ®Google Scholar
• Shad MU, Preskorn SH. A possible bupropion and imipramine interaction. J Clin Psychopharmacol 1997;17(2):118-19
   PubMed Web of Science ®Google Scholar
• DeVane CL, Laizure SC, Stewart JT, et al. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990;10(5):328-32
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Study WELL AK1B1001. The pharmacokinetics and tolerability of Wellbutrin SR after oral administration of a single 150 mg dose in patients with liver cirrhosis and healthy volunteers. GlaxoSmithKline, Research Triangle Park, NC; 1997
   Google Scholar
• Earhart AD, Patrikeeva S, Wang X, et al. Transplacental transfer and metabolism of bupropion. J Matern Fetal Neonatal Med 2010;23(5):409-16
   PubMed Web of Science ®Google Scholar
• Alwan S, Reefhuis J, Botto LD, et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010;203(1):52 e1 6
   PubMed Web of Science ®Google Scholar
• Thyagarajan V, Robin Clifford C, Wurst KE, et al. Bupropion therapy in pregnancy and the occurrence of cardiovascular malformations in infants. Pharmacoepidemiol Drug Saf 2012;21(11):1240-2
   PubMed Web of Science ®Google Scholar
• Worrall SP, Almond MK, Dhillon S. Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study. Nephron Clin Pract 2004;97(3):c83-9
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Koivuviita N, Tolonen A, et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol 2007;64(2):165-73
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Study 40UKA. The disposition of bupropion and its basic metabolites in young and elderly healthy volunteers. GlaxoSmithKline, Research Triangle Park, NC; 1984
   Google Scholar
• Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995;35(9):876-84
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Study WELL AK130930. A 7-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-Release Bupropion Hydrochloride (WELLBUTRIN XL) and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-up Phase. GlaxoSmithKline, Research Triangle Park, NC; 2002
   Google Scholar
• GlaxoSmithKline. Study WELL AK130936. A 7-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-Release Bupropion Hydrochloride (WELLBUTRIN XL) and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-up Phase. GlaxoSmithKline, Research Triangle Park, NC; 2002
   Google Scholar
• GlaxoSmithKline. Study WELL 100006. A 7-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-Release Bupropion Hydrochloride (WELLBUTRIN XL) and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-up Phase. GlaxoSmithKline, Research Triangle Park, NC; 2003
   Google Scholar
• Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29(3):259-66
   PubMed Web of Science ®Google Scholar
• Kumar S, Kodela S, Detweiler JG, et al. Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature. Gen Hosp Psychiatry 2011;33(6):612-17
   PubMed Web of Science ®Google Scholar
• Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991;52(11):450-6
   PubMed Web of Science ®Google Scholar
• Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998;59(7):366-73
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract 2005;59(12):1435-40
   PubMed Web of Science ®Google Scholar
• Wightman DS, Foster VJ, Krishen A, et al. Meta-analysis of suicidality in placebo-controlled clinical trials of adults taking bupropion. Prim Care Companion J Clin Psychiatry 2010;12(5):e1-e8
   Google Scholar
• Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009;339:b2880
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Patrick AR, Solomon DH, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry 2010;67(5):497-506
   PubMed Web of Science ®Google Scholar
• Thase ME, Haight BR, Johnson MC, et al. A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 2008;28(3):302-7
   PubMed Web of Science ®Google Scholar
• Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003;24(10):946-55
   PubMed Web of Science ®Google Scholar
• Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med 2006;119(12):1080-7
   PubMed Web of Science ®Google Scholar
• Drug Product Database. Health Canada. Health Canada, Ontario, Canada; 2013. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php [Last accessed 12 March 2013]
   Google Scholar
• Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287(14):1840-7
   PubMed Web of Science ®Google Scholar